What did @therestoreclinic actually say?
The creator called a 200mg testosterone injection every 10 days "absolutely terrible" on two counts: the dose is too high for most people, and the frequency is poorly matched to individual physiology. They argued that injection timing should be based on SHBG and albumin levels, that smaller and more frequent injections tend to work better for most patients, and they warned viewers to avoid any provider pushing "rheumatase inhibitors."
That last point deserves immediate attention. There is no drug called a "rheumatase inhibitor" in endocrinology or TRT practice. The creator almost certainly meant aromatase inhibitors, which are sometimes prescribed alongside testosterone to manage estrogen conversion. That is either a verbal slip or a significant terminology error, and it undercuts an otherwise reasonable clinical argument.
Does the science back this up?
Mostly, yes. The evidence on testosterone cypionate or enanthate dosing consistently shows that 200mg in a single injection produces supraphysiologic testosterone peaks followed by a steep trough, a pattern associated with mood swings, erythrocytosis risk, and suboptimal symptom control.
Ramasamy et al. (2014, Journal of Urology) and Bhasin et al. (2010, Journal of Clinical Endocrinology and Metabolism) both support individualized dosing based on pharmacokinetics and patient response rather than one-size protocols. The Endocrine Society's clinical practice guidelines recommend dose titration based on mid-cycle or trough testosterone levels, not fixed intervals. The creator's point about SHBG being relevant to injection frequency is also well-supported. Men with higher SHBG bind more testosterone and may clear it differently, which affects how often injections are needed to maintain stable free testosterone levels.
What did they get wrong (or right)?
They got the core clinical argument right. A blanket 200mg every 10 days protocol, applied without individual lab work, is a poor approach to TRT management. The research supports smaller, more frequent doses, such as twice-weekly or even subcutaneous micro-dosing protocols, as producing more stable serum testosterone levels.
What they got wrong is the terminology. "Rheumatase inhibitors" do not exist. Aromatase inhibitors like anastrozole or exemestane are sometimes used in TRT protocols to reduce estrogen conversion, though their routine use is debated. Morgentaler et al. (2015, Mayo Clinic Proceedings) noted that aggressive estrogen suppression in TRT patients can reduce bone density and libido without clear benefit. The creator's point, however mangled the terminology, that over-reliance on these drugs as a default protocol is worth questioning, has some legitimate clinical basis. But calling out a made-up drug class is not a clean way to make that argument.
- Correctly identified: 200mg single injections drive hormone spikes, not stability
- Correctly identified: SHBG affects how individuals metabolize testosterone
- Correctly identified: frequency should be individualized, not defaulted
- Got wrong: named a drug class that does not exist
What should you actually know?
Standard TRT dosing for hypogonadism in clinical guidelines ranges from 75mg to 100mg per week of testosterone cypionate or enanthate, often split into twice-weekly injections to flatten the peak-trough curve. The American Urological Association and Endocrine Society both recommend monitoring hematocrit, PSA, and testosterone levels at regular intervals, with dose adjustments based on labs and symptom response.
The creator's broader message, that a rigid, high-dose, infrequent injection protocol applied without individual assessment is problematic, is accurate. But no single protocol is right for every patient, and anyone managing TRT without regular lab monitoring and a licensed provider is taking a real risk. SHBG, albumin, hematocrit, and symptom tracking all inform how a protocol should be adjusted over time. A TikTok comment thread is not a substitute for that process.